Anti-Cancer Drug Linked to Tumor Shrinkage in Patients with Advanced Differentiated Thyroid Cancer

Researchers tested the effectiveness of lenvatinib in patients with advanced, progressive differentiated thyroid cancer (DTC) that does not respond to conventional radioiodine therapy. Data demonstrated a partial response in 45%-50% of the 58 patients enrolled in the study.

Read the whole article on

More from